Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)

[1]  Kevin B. Jones,et al.  Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. , 2012, Cancer cell.

[2]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.

[3]  M. Szendrői,et al.  Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma , 2011, Diagnostic pathology.

[4]  A. D. De Marzo,et al.  Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms , 2011, Oncotarget.

[5]  A. Giordano,et al.  Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications , 2011, BMC medicine.

[6]  G. Ippolito,et al.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis , 2011, BMC medicine.

[7]  J. Gribben,et al.  EZH2 Y641 mutations in follicular lymphoma , 2011, Leukemia.

[8]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[9]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[10]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[11]  Teruhiko Yoshida,et al.  Gene Expression Profiling of Synovial Sarcoma: Distinct Signature of Poorly Differentiated Type , 2010, The American journal of surgical pathology.

[12]  Guy Sauvageau,et al.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.

[13]  L. Boyer,et al.  Polycomb group proteins set the stage for early lineage commitment. , 2010, Cell stem cell.

[14]  H. Yoshikawa,et al.  Synovial Sarcoma Is a Stem Cell Malignancy , 2010, Stem cells.

[15]  Qiang Yu,et al.  Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression , 2010, Cell Death and Differentiation.

[16]  Mengzhong Liu,et al.  Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma , 2009, BMC Cancer.

[17]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[18]  A. Donfrancesco,et al.  Deregulated expression of miR-26a and Ezh2 in Rhabdomyosarcoma , 2009, Cell cycle.

[19]  M. Osaki,et al.  High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas. , 2008, Molecular medicine reports.

[20]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[21]  Baocun Sun,et al.  The diagnostic value of SYT‐SSX detected by reverse transcriptase–polymerase chain reaction (RT‐PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma: A review and prospective study of 255 cases , 2008, Cancer science.

[22]  M. van de Rijn,et al.  Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. , 2008, Cancer research.

[23]  D. Ghosh,et al.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.

[24]  T. Paterek,et al.  An experimental test of non-local realism , 2007, Nature.

[25]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[26]  J. Nap,et al.  The (Epi)genetics of human synovial sarcoma , 2007, Genes, chromosomes & cancer.

[27]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.

[28]  H. Inoue,et al.  Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. , 2005, Cancer letters.

[29]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[31]  S. Hirohashi,et al.  Prognostic significance of grading and staging systems using MIB‐1 score in adult patients with soft tissue sarcoma of the extremities and trunk , 2002, Cancer.

[32]  M. Ladanyi.  Fusions of the SYT and SSX genes in synovial sarcoma , 2001, Oncogene.

[33]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[34]  R. Kingston,et al.  Stabilization of Chromatin Structure by PRC1, a Polycomb Complex , 1999, Cell.

[35]  C. Fletcher,et al.  Soft Tissue Tumors , 1995, Current Topics in Pathology.

[36]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[37]  Y. Zeng,et al.  High Expression of H 3 K 27 me 3 in Human Hepatocellular Carcinomas Correlates Closely with Vascular Invasion and Predicts Worse Prognosis in Patients , 2011 .

[38]  M. Ladanyi,et al.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. , 2002, Cancer research.

[39]  C. Fisher.  Synovial sarcoma. , 1998, Annals of diagnostic pathology.